

Richard J Edmondson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8403669/publications.pdf>

Version: 2024-02-01

48
papers

3,456
citations

257101

24
h-index

214527

47
g-index

48
all docs

48
docs citations

48
times ranked

5251
citing authors

#	ARTICLE	IF	CITATIONS
1	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	12.8	839
2	Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3388-3397.	0.8	398
3	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. <i>Modern Pathology</i> , 2015, 28, 836-844.	2.9	343
4	Copy number signatures and mutational processes in ovarian carcinoma. <i>Nature Genetics</i> , 2018, 50, 1262-1270.	9.4	320
5	Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors. <i>Clinical Cancer Research</i> , 2010, 16, 2344-2351.	3.2	244
6	Engineering microrobots for targeted cancer therapies from a medical perspective. <i>Nature Communications</i> , 2020, 11, 5618.	5.8	220
7	Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival. <i>Cancer Research</i> , 2012, 72, 5675-5682.	0.4	109
8	Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions. <i>Gynecologic Oncology</i> , 2016, 143, 287-293.	0.6	77
9	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. <i>Modern Pathology</i> , 2016, 29, 174-181.	2.9	68
10	A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity. <i>Nature Communications</i> , 2020, 11, 822.	5.8	62
11	Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib. <i>Clinical Cancer Research</i> , 2017, 23, 2050-2060.	3.2	60
12	Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies. <i>Modern Pathology</i> , 2017, 30, 459-468.	2.9	53
13	DNA damage repair in ovarian cancer: unlocking the heterogeneity. <i>Journal of Ovarian Research</i> , 2018, 11, 50.	1.3	49
14	The Use of Ovarian Cancer Cells from Patients Undergoing Surgery to Generate Primary Cultures Capable of Undergoing Functional Analysis. <i>PLoS ONE</i> , 2014, 9, e90604.	1.1	42
15	p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial. <i>Modern Pathology</i> , 2022, 35, 1475-1483.	2.9	39
16	Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer. <i>Journal of Immunotherapy</i> , 2018, 41, 130-140.	1.2	38
17	The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: A prospective case control study. <i>Gynecologic Oncology</i> , 2018, 148, 154-160.	0.6	36
18	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. <i>Modern Pathology</i> , 2018, 31, 1851-1861.	2.9	35

#	ARTICLE	IF	CITATIONS
19	Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial “ ANZGOG 0903. <i>Gynecologic Oncology</i> , 2019, 154, 29-37.	0.6	35
20	Epithelial ovarian cancer risk: A review of the current genetic landscape. <i>Clinical Genetics</i> , 2020, 97, 54-63.	1.0	31
21	Human spermbots for patient-representative 3D ovarian cancer cell treatment. <i>Nanoscale</i> , 2020, 12, 20467-20481.	2.8	31
22	First-Line Management of Advanced High-Grade Serous Ovarian Cancer. <i>Current Oncology Reports</i> , 2020, 22, 64.	1.8	30
23	Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A Trans PORTEC initiative. <i>Gynecologic Oncology</i> , 2017, 146, 327-333.	0.6	26
24	BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study. <i>European Journal of Cancer</i> , 2020, 136, 169-175.	1.3	26
25	Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. <i>European Journal of Human Genetics</i> , 2020, 28, 1541-1547.	1.4	22
26	Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1519-1531.	2.0	21
27	Prevalence of germline pathogenic <i>BRCA1/2</i> variants in sequential epithelial ovarian cancer cases. <i>Journal of Medical Genetics</i> , 2019, 56, 301-307.	1.5	21
28	Decision-Making in Gynaecological Oncology Multidisciplinary Team Meetings: A Cross-Sectional, Observational Study of Ovarian Cancer Cases. <i>Oncology Research and Treatment</i> , 2020, 43, 70-77.	0.8	20
29	Detection of MCM5 as a novel non-invasive aid for the diagnosis of endometrial and ovarian tumours. <i>BMC Cancer</i> , 2020, 20, 1000.	1.1	19
30	Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1122-1132.	1.1	18
31	A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial. <i>Gynecologic Oncology</i> , 2021, 163, 72-78.	0.6	17
32	Cervical cancer and “COVID” an assessment of the initial effect of the pandemic and subsequent projection of impact for women in England: A cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1133-1139.	1.1	16
33	Specialist oncological surgery for removal of the ovaries and fallopian tubes in <i>BRCA1</i> and <i>BRCA2</i> pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels. <i>International Journal of Cancer</i> , 2021, 148, 1155-1163.	2.3	13
34	PROgesterone Therapy for Endometrial Cancer Prevention in Obese Women (PROTEC) Trial: A Feasibility Study. <i>Cancer Prevention Research</i> , 2021, 14, 263-274.	0.7	11
35	Uptake and efficacy of bilateral risk reducing surgery in unaffected female <i>BRCA1</i> and <i>BRCA2</i> carriers. <i>Journal of Medical Genetics</i> , 2022, 59, 133-140.	1.5	11
36	Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1004-1011.	1.2	9

#	ARTICLE	IF	CITATIONS
37	PARAGON: A phase 2 study of anastrozole (An) in patients with estrogen receptor(ER) and / progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary.. Journal of Clinical Oncology, 2018, 36, 5524-5524.	0.8	8
38	Phosphatase and Tensin Homolog Is a Potential Target for Ovarian Cancer Sensitization to Cytotoxic Agents. International Journal of Gynecological Cancer, 2016, 26, 632-639.	1.2	7
39	A Prospective Study to Identify Rates of SARS-CoV-2 Virus in the Peritoneum and Lower Genital Tract of Patients Having Surgery: An Observational Study. Journal of Minimally Invasive Gynecology, 2021, 28, 1633-1636.	0.3	6
40	Phase II study of anastrozole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trialâ€”ANZGOG 0903.. Journal of Clinical Oncology, 2016, 34, 5520-5520.	0.8	5
41	Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 2021, 163, 524-530.	0.6	5
42	Dominantâ€”negative pathogenic variant <scp>BRIP1</scp> c.<scp>1045G</scp>>C is a highâ€”risk allele for nonâ€”mucinous epithelial ovarian cancer: A caseâ€”control study. Clinical Genetics, 2022, 101, 48-54.	1.0	3
43	STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer.. Journal of Clinical Oncology, 2018, 36, TPS5615-TPS5615.	0.8	3
44	Functional characterisation of a novel ovarian cancer cell line, NUOC-1. Oncotarget, 2017, 8, 26832-26844.	0.8	3
45	c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial. BMC Medicine, 2022, 20, 59.	2.3	3
46	Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study. BMC Cancer, 2021, 21, 378.	1.1	2
47	BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?. British Journal of Cancer, 2022, 127, 163-167.	2.9	2
48	Prognostic models for predicting recurrence and survival in women with endometrial cancer. The Cochrane Library, 2021, 2021, .	1.5	0